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D u et os i d ee ﬀects in the form of meningoencephalitis in the interrupted phase II AN1792 trial of active antiamyloid β(Aβ)
immunization against Alzheimer’s disease (AD), there has been concern that anti-Aβ immunization may cause destructive
neuroinﬂammation.Here, we report on two patientsfulﬁllingclinicalAD criteria whowere diagnosedwithLymeneuroborreliosis
during screening before inclusion in anti-Aβ immunotherapy trials. The two cases illustrate the necessity of careful biochemical
screening for neuroinﬂammatory/neuroinfectious conditions before an AD diagnosis is made and before clinical AD patients are
included in trials of therapy that could impact the immune system. Should the two cases have been included and deteriorated,
additional investigations might have led to the erroneous conclusion that therapy-induced meningoencephalitis had occurred.
1.Introduction
Clinical trials of disease-modifying treatments for AD have
been struck by adverse events involving the immune sys-
tem. In the clinical trial of the active antiamyloid β(Aβ)
vaccine AN1792, a small but notable number of patients
developed meningoencephalitis [1], and treatment with the
passive anti-Aβ immunotherapy AAB001 led to vasogenic
edema in some individuals [2]. The Aβ immunogens that
are now being used in the second generation of active
immunization trials have been modiﬁed to reduce the risk
of meningoencephalitis. However, academia, industry, and
regulators are on their toes to identify immunological side
eﬀectsasearlyaspossibletoavoidpatientinjury.Therefore,it
is ofutmost importance to identify and excludepatients who
fulﬁll clinical AD criteria but who already before the start of
therapy show biochemical signs of neuroinﬂammation.
A number of standard laboratory tests are useful for
this purpose. Typical laboratory ﬁndings in patients with
neuroinﬂammatory/neuroinfectious conditions include im-
paired blood-brain barrier function, as reﬂected by an
elevated ratio of albumin concentrations in cerebrospinal
ﬂuid (CSF) and serum/plasma, CSF monocytosis and IgG
and IgM bands selectively in CSF [3, 4]. These changes are
also seen in therapy-induced meningoencephalitis [1]. We
here present two clinical AD cases who were diagnosed with
Lyme neuroborreliosis (LNB) during screening for eligibility
to enter an anti-Aβ immunotherapy trial. Should the two
cases have been included and deteriorated, additional
investigations might have led to the erroneous conclusion
that therapy-induced meningoencephalitis had occurred.
2.Case Descriptions
NO is a 70-year-old retired man. His health history is
remarkable for a cholecystectomy in 2001 that was followed
by confusion. An epileptic seizure was suspected and the
patient was treated with carbamazepine for a short period.
He did not have any new seizures after carbamazepine was
withdrawn. The patient has a positive family history of AD
withbothhisgrandfatherandmotherhavingbeendiagnosed
with the disease.2 International Journal of Alzheimer’s Disease
Table 1: Biochemical ﬁndings in the cerebrospinal ﬂuid of two patients with cognitive problems and Lyme neuroborreliosis.
Case Albumin ratio
(<10.2) IgG-index (<0.63) IgM-index
(<0.060)
CSF monocytes
(<5/μL)
Serum anti-Borrelia
antibodies
CSF anti-Borrelia
antibodies
Man, 70 years 13.5 0.49 0.28 108 Negative Positive
Woman,68 years 33.4 1.82 0.93 84 Negative Positive
Values in parentheses show laboratory reference limits.
In 1995, NO started to complainof cognitive decline that
progressed over the years with aphasia, apraxia, and agnosia.
He developedspatial deﬁcitswith orientation diﬃcultiesand
a strong tendency to misplace belongings. In 2002, he was
diagnosed with AD. A magnetic resonance imaging (MRI)
scanofthebrainwasnormalwithnoatrophyorwhitematter
changes. EEG showed slow postcentral rhythm (7Hz), and
single positron emission computed tomography (SPECT) of
the brain revealed frontotemporal hypoperfusion with left-
side predominance. CSF analyses showed slightly elevated
albumin ratioof12(<10)asa sign ofmildly impaired blood-
brain barrier function, normal cell counts, elevated total-tau
(T-tau) of 589ng/L (laboratory reference limit <400ng/L),
and normal Aβ1-42 concentration 495ng/L (>450). He
was heterozygous for the Alzheimer-associated ε4 allele of
the apolipoprotein E gene. Neurological examination was
normal, and the neuropsychological proﬁle and clinical
evaluation were consistent with AD. The patient started
treatment with galantamine. His cognition improved with
the minimental state examination (MMSE) score rising from
22 to 28 points.
In November2006, the patient was screened for a clinical
trial of active immunization against Aβ. His cognition had
been rather stable over the four years on treatment with only
a minor decrease of the MMSE score from 28 to 25. He had
nosomaticcomplaintsandhissomaticstatuswasnormal.He
showed no symptoms of infection and had no neurological
complaints. An MRI scan of the brain showed slight atrophy
with mild white matter changes consistent with AD.
A lumbar puncture was performed at baseline before
inclusion in the trial, and the biomarkers for AD, T-tau,
phospho-tau181 (P-tau181), and Aβ1-42 were 520 (<400), 96
(<80), and 460 (>450) ng/L, respectively, which is consistent
with AD. The albumin ratio was further elevated, and,
surprisingly, CSF monocyte counts were high and so was the
IgM-index (Table 1). Agarose gel electrophoresis of serum
andCSFfollowedbyimmunoblottingagainst IgMsupported
ongoing intrathecal IgM production. This neurochemical
picture is consistent with neuroinﬂammation. Anti-Borrelia
titerswere positive inCSF butnegative inserum. The patient
was treated with standard doxycycline 200 mg twice a day
for 10 days. He was then followed with repeated CSF taps
for 1.5 year during which his albumin ratio and cell counts
were normalized. However, T-tau and P-tau181 remained
pathologically elevated and Aβ1-42 turned low indicating an
ongoing AD process. Accordingly, the patient has continued
to deteriorate cognitively during the followup period.
The next case, BS, is a 68-year-old woman. She is occu-
pied as a hairdresser, still working part-time. Her health
history is unremarkable. In 2003, she started to suﬀer from
progressive cognitivedeterioration,andinFebruary2006she
fulﬁlled clinical criteria for AD and started treatment with
galantamine. The diagnosis was based on the anamnestic
record and supported by ﬁndings on MRI and SPECT, as
well as neuropsychological test results. To further secure
her diagnosis, a CSF tap was planned but she declined this
investigation. The patient wast e r r i ﬁ e do fh e rd i a g n o s i sa n d
wanted to ﬁght it the best she could. She had heard of ongo-
ingimmunizationtrialsattheKarolinskaUniversityHospital
and was referred for being evaluated for eligibility. As a part
of this evaluation, a baseline CSF tap was mandatory and she
agreed on this. The results showed completely normal T-tau,
P-tau181,andAβ1-42 concentrationsin CSFspeaking against
AD. However, the albumin ratio was strongly elevated, CSF
monocyte counts high, and both the IgG- and IgM-indices
elevated (Table 1) with oligoclonal IgG and IgM bands
selectively inCSFasa furthersign ofintrathecal IgGand IgM
production. The anti-Borrelia titerinserum was negative but
positive in CSF. She was treated with standard doxycycline
200mg twice a day for 10 days. She was then followed
with repeated CSF taps for 1.5 year showing normalization
of the blood-brain barrier function and cell counts. Her
cognitive status slowly improved during this period and the
AD diagnosis was disposed.
3.Discussion
The two cases illustrate the necessity of identifying treatable
causes of memory problems. The case histories are of
relevance both to clinicians who evaluate and treat patients
with cognitive problems and also to the pharmaceutical
industry that designs trials of drug candidates that might
impact the immune system. For one of the two cases, BS,
the spinal tap was essential with the CSF test results radically
changing the diagnosis from an incurable, ultimately fatal
disease to a treatable spirochetal infection. NO suﬀers from
AD but during the disease process he contracted LNB that
could have been mistaken for a side eﬀect of the anti-Aβ
immunization should he have been included in the trial.
LNB is a multisystem disease caused by infection with
the spirochete Borrelia burgdorferi and the most common
infectious cause of chronic neuroinﬂammation. Neurologic
complications of LNB include encephalitis, meningitis, and
dementia,aswell asa broad rangeofperipheralneuropathies
[5]. The many symptoms of LNB may mimic neurodegener-
ative diseases, such as AD and amyotrophic lateral sclerosis
(ALS). Although there is no strong evidence that these
diseases are caused by spirochetal infections, diagnosis of
each must rule out the possibility of LNB.International Journal of Alzheimer’s Disease 3
To the best of our knowledge, there are no published
studies on the prevalence of LNB in patients attending a
memory clinic. At least four studies have examined the
prevalence of anti-Borrelia burgdorferi antibodies in serum
in AD cases and controls without ﬁnding evidence of
an association with AD [6–9]. Two cases of LNB were
diagnosed in 1,089 consecutive patients (aged 23–89 years)
who underwent lumbar puncture as a part of the routine
diagnostic evaluation between February 2001 and March
2007 at the specialized memory clinic in Malm¨ o[ 10], but
it should be noted that these patients were selected referral
patients. The prevalence of intrathecal immunoglobulin
production in AD patients ranges from 5 to 20% in diﬀerent
studies [11–13].
In conclusion, analysis of CSF taken from patients
at baseline, before treatment, could be useful in clinical
trials for identifying and excluding individuals with chronic
infectious or inﬂammatory CNS disorders that can mimic or
aggravate the symptoms of AD. The inclusion of such cases
in trials could result in the wrong conclusion that an adverse
eﬀect, such as encephalitis, was related to the drug being
tested.Baseline CSFsamples canalso beused incomparisons
with CSF collected after treatment initiation. The beneﬁt
of such comparisons is that even minor inﬂammatory
activation within the CNS, as a result of adverse eﬀects of
t h ed r u g ,c a nb ei d e n t i ﬁ e d .T h u s ,C S Fb i o m a r k e r sc o u l d
allow safety monitoring during clinical trials. Longitudinal
CSF sampling during the treatment period might indicate
whether a certain drug induces harmful immune activation
over the long term.
Considering CSF analyses in a broader perspective, we
t h i n kas p i n a lt a ps h o u l db ec o n s i d e r e di ne v e r yp a t i e n t
who seeks medical advice for cognitive problems, at least in
areas where LNB is endemic and in particular if the clinical
presentation is atypical. The safety and acceptability of the
procedure support this view [10, 14, 15].
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